Atlas Capital Advisors Inc. Has $1.79 Million Position in Bristol Myers Squibb Company (NYSE:BMY)

Key Points

• Atlas Capital Advisors Inc. increased its stake in Bristol Myers Squibb by 55.9%, acquiring an additional 10,501 shares, bringing its total holdings to 29,286 shares valued at approximately $1,786,000.
• During the 1st quarter, several hedge funds, including Marcum Wealth LLC and Beacon Investment Advisory Services Inc., also raised their positions in Bristol Myers Squibb, reflecting a broader trend of institutional investors collectively owning 76.41% of the company's stock.
• Bristol Myers Squibb reported an EPS of $1.46 for the last quarter, exceeding estimates, and a revenue of $12.27 billion, indicating a slight year-over-year increase of 0.6% compared to the same quarter last year.

Atlas Capital Advisors Inc. boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 55.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,286 shares of the biopharmaceutical company's stock after buying an additional 10,501 shares during the period. Atlas Capital Advisors Inc.'s holdings in Bristol Myers Squibb were worth $1,786,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its position in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Bank Pictet & Cie Europe AG acquired a new position in Bristol Myers Squibb during the 4th quarter worth approximately $13,094,000. Scotia Capital Inc. boosted its position in Bristol Myers Squibb by 66.1% during the 4th quarter. Scotia Capital Inc. now owns 342,885 shares of the biopharmaceutical company's stock worth $19,394,000 after acquiring an additional 136,425 shares during the last quarter. Legacy Financial Advisors Inc. raised its stake in shares of Bristol Myers Squibb by 25.0% during the 4th quarter. Legacy Financial Advisors Inc. now owns 12,568 shares of the biopharmaceutical company's stock worth $711,000 after purchasing an additional 2,511 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its holdings in Bristol Myers Squibb by 25.3% during the 4th quarter. Kennedy Capital Management LLC now owns 104,751 shares of the biopharmaceutical company's stock valued at $5,925,000 after purchasing an additional 21,118 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

BMY stock traded down $0.04 on Monday, hitting $45.91. 8,663,225 shares of the company's stock traded hands, compared to its average volume of 13,566,976. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The stock has a market cap of $93.45 billion, a price-to-earnings ratio of 18.51, a P/E/G ratio of 2.35 and a beta of 0.36. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The stock has a fifty day moving average of $47.26 and a 200-day moving average of $51.72.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period last year, the business posted $2.07 EPS. Bristol Myers Squibb's revenue was up .6% compared to the same quarter last year. On average, analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.4%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 100.00%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BMY. Piper Sandler initiated coverage on Bristol Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target on the stock. Argus raised Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Daiwa America downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Jefferies Financial Group cut their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Finally, Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $56.38.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.